Full history for every metric is available with a Kvantra account
Hologic, Inc. (HOLX)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3,776 | 5,632 | 4,863 | 4,030 | 4,030 | 4,101 | 4,126 |
| Operating profit | $m | 714 | 722 | |||||
| Net profit | $m | 1,115 | 1,872 | 1,302 | 456 | 790 | 566 | 544 |
| EPS reported | $ | 2.49 | 2.40 | |||||
| Operating cashflow per share | $ | 4.65 | 4.14 | |||||
| Capex per share | $ | 0.60 | 0.26 | |||||
| FCF per share | $ | 4.05 | 3.88 | |||||
| Free cash flow | $m | 920 | 1,000 | |||||
| Net debt | $m | 305 | 144 | |||||
| Book value equity | $m | 5,048 | 5,245 | |||||
| Book value per share | $ | 22.18 | 23.22 | |||||
| Number of shares | m | 227.57 | 225.88 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 26.99 | 31.67 | |||||
| P/B LTM | x | 3.02 | 3.24 | |||||
| P/S LTM | x | 3.72 | 4.11 | |||||
| P/FCF LTM | x | 16.60 | 16.98 | |||||
| EV/EBITDA LTM | x | 15.57 | 16.88 | |||||
| EV/Sales LTM | x | 3.89 | 4.15 | |||||
| Earnings Yield LTM | % | 3.71% | 3.16% | |||||
| FCF Yield | % | 6.03% | 5.89% | |||||
| Quality | ||||||||
| ROE | % | 11.21% | 11.13% | |||||
| ROIC | % | 7.35% | 7.17% | |||||
| Operating margin | % | 17.42% | 23.34% | |||||
| Gross margin | % | 61.00% | 57.74% | |||||
| FCF/Sales | % | 22.44% | 27.89% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -25.00% | -24.29% | |||||
| Sales Growth YoY | % | +1.74% | +2.16% | |||||
| Net Income Growth YoY | % | -28.35% | -26.90% | |||||
| FCF Growth | % | -19.64% | -9.56% | |||||
| Operating Profit Growth | % | -19.07% | -23.81% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.35 | 0.40 | |||||
| Net Debt/EBITDA | x | 0.65 | 0.38 | |||||
| EBIT/Net interest | x | 16.73 | 11.02 | |||||
| Net debt/market cap | % | 2.00% | 0.85% | |||||
| Net debt/Equity | x | 0.06 | 0.03 | |||||
| Gross debt/equity | x | 0.52 | 0.48 | |||||
Company overview
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hologic, Inc. (HOLX)
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free